RxSight’s Q2 2026 Earnings Call: Growth Strategy Shifts, Guidance Withdrawal, and Timeline Delays Clash

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $33.7M, including $6.5M from Alcon collaboration; product sales were $27.2M, down 19% YOY
• EPS: Net loss of $0.29 per basic and diluted share; adjusted net loss of $0.11 per share
• Gross Margin: 71.2% excluding Alcon revenue, compared to 74.9% in the prior year period; 76.7% including Alcon revenue

Business Commentary:

Revenue Performance and Market Challenges:

• RxSight reported second quarter total company revenue of $33.7 million, including $6.5 million from the Alcon collaboration.
• Excluding Alcon-related revenue, product sales were $27.2 million, down 19% compared to the prior year period.
• The decline was attributed to heightened competitive trialing and broader marketplace headwinds.

LAL Unit Volume and Sales Trends:

• LAL unit volumes were 24,917, down 9% from the prior year period.
• LAL procedure volume translated into $24.5 million in sales, representing 90% of RxSight product revenue.
• The decrease in volume and sales was linked to competitive activity and product trialing.

Strategic Collaboration with Alcon:

• RxSight announced a collaboration with Alcon, bringing in $200 million in upfront and potential future milestone payments.
• This partnership is expected to generate significant long-term royalties and provides non-dilutive capital.
• The collaboration is seen as a major milestone and external validation of RxSight's technology.

Withdrawal of Financial Guidance:

• RxSight decided to withdraw its previously issued four-year financial guidance.
• The company cited the need for a thorough assessment of the business to identify underlying challenges and determine the best long-term actions.
• They plan to resume formal guidance in early 2027.

Focus on Commercial Strategy and Sales Expansion:

• RxSight plans to double its U.S. sales team to enhance commercial strategy and customer support.
• The expansion aims to increase utilization across the installed base and improve workflow integration.
• Funding for the expansion will come from reallocating resources within the organization.

Sentiment Analysis:

Overall Tone: Positive

• CEO states 'the value of adjustability remains compelling' and 'physicians recognize the technology's differentiation.' He believes 'there's an opportunity to significantly enhance our strategy and execution' and that 'this has tremendous potential and that we've just scratched the surface.'

Q&A:

• Question from Robbie Marcus (J.P. Morgan): what was it about ArcSight and the company and the product and the opportunity that made you step in here?
  Response: The technology is a category breakthrough in cataract surgery with strong physician endorsement, and the CEO sees similarities to his past experience building new categories in eye care.

• Question from Robbie Marcus (J.P. Morgan): Any preliminary views on what do you think happened that led to the deceleration and growth and the lower utilization and any early thoughts on how you might be able to go and address this?
  Response: The CEO believes the company is pivoting from building a broad user base to driving depth of utilization per practice, which requires a different strategy. Physicians still believe the technology is best and have not capped usage.

• Question from Jacqueline (Orrick): With the placement of your first LDD rental unit, moving forward, how much of your LDD pipeline do you anticipate shifting toward rental units versus capital purchases?
  Response: The company is open to more rental contracts, especially in international markets, but did not provide a specific target figure.

• Question from Jacqueline (Orrick): With the recent regulatory approvals... has the Alcon collaboration altered your standalone OUS commercial strategy at all?
  Response: The standalone international strategy is separate from the Alcon partnership; the focus is on thoughtful expansion in high-potential markets, while Alcon aims to broaden adjustability across more lenses.

• Question from Robbie Marcus (J.P. Morgan): What can you share about your success in your prior roles or the key success factors... that you think might be applicable to RxSight?
  Response: Key factors are operating discipline, close customer connectivity, and leveraging education to propagate the technology's real-world results.

• Question from Robbie Marcus (J.P. Morgan): Could you envision doing similar agreements with other companies?
  Response: The focus is currently on maximizing the Alcon partnership; the non-exclusive nature provides options long-term but is not the immediate priority.

• Question from Stephanie Elgazy (Bank of America): How you're thinking about [improving utilization, expanding sales force] in the context of the guide being withdrawn...
  Response: Withdrawing guidance provides flexibility to make necessary strategic changes to orient the business for long-term growth, not a signal of performance issues.

• Question from Young Lee (Jefferies): since when do you think you'd be able to finish [the assessment]?
  Response: Updates will be provided on the next quarterly call; the goal is to complete the assessment so the company can provide 2027 guidance and move to a growth trajectory.

• Question from Young Lee (Jefferies): what were some of the issues or frictions or challenges they highlighted to you?
  Response: Challenges are largely around workflow optimization and patient selection, which physicians approach as solvable with education and best practices sharing.

• Question from Steve Stephens (Stifel): from a physician or from a practice standpoint, would love to hear your views on the intersection between drugs and devices in cataract and refractive surgery...
  Response: The trend is patients demanding better outcomes, driving physicians to adopt technologies (like devices) that deliver meaningful, precise results, which aligns with RxSight's value proposition.

Contradiction Point 1

Cause and Solution for Growth Deceleration

Contradiction on whether the growth issue was addressed or if new challenges emerged.

Robbie Marcus (J.P. Morgan) - Robbie Marcus (J.P. Morgan)

2026Q2: Regarding growth deceleration, the company is pivoting from establishing a broad user base to driving depth of utilization. Physicians still believe in the technology and report capacity to perform more LAL procedures. - Aziz Motibala(CEO)

What steps are you taking to address the deceleration in growth and lower utilization following your involvement at RxSight? - Robbie Marcus (J.P. Morgan)

2026Q2: The company is shifting its strategy from building a broad user base to driving depth of utilization within existing practices. This 'pivot from breadth to depth' requires a different approach. Surgeons still believe the LAL is the best technology and could perform more procedures, indicating the issue is strategy execution, not market saturation. - Aziz Mottiwala(CEO)

Contradiction Point 2

Timeline for Business Assessment Update

Contradiction on the timing for providing details on the business assessment.

Young Lee (Jefferies) - Young Lee (Jefferies)

2026Q2: Updates will be provided on the next quarterly call. The process is intended to be disciplined and timely, with a commitment to issuing 2027 financial guidance at year-end. - Aziz Motibala(CEO)

When will the business assessment be completed, what key KPIs are prioritized, and what customer challenges were highlighted? - Young Li (Jefferies)

2026Q2: The assessment timeline is being approached with discipline and speed. More details will be provided in the next quarter. The ultimate goal is to provide 2027 financial guidance at year-end... - Aziz Mottiwala(CEO)

Contradiction Point 3

2026 Growth Outlook and Guidance Specificity

Contradiction on providing specific growth guidance for 2026.

Stephanie Elgazy (Bank of America) - Stephanie Elgazy (Bank of America)

2026Q2: The withdrawn guidance provides flexibility to make necessary changes without being constrained by prior expectations. - Aziz Motibala(CEO)

How does the company's vision align with recent initiatives like improving utilization and expanding the sales force, and does the withdrawn guidance indicate significant changes? - David Saxon (Needham)

2026Q1: LAL growth for 2026 is still expected to be in the low single-digit range, with sequential improvement by quarter. - Mark Wilterding(CFO)

Contradiction Point 4

Strategic Focus for Driving Utilization and Growth

Contradiction on the primary lever for growth, shifting from broad user base to deep utilization.

Robbie Marcus (J.P. Morgan) - Robbie Marcus (J.P. Morgan)

2026Q2: The company is pivoting from establishing a broad user base to driving depth of utilization. - Aziz Motibala(CEO)

What caused the deceleration in growth and lower utilization, and how will you address it? - Robbie Marcus (JPMorgan)

2026Q1: The company is confident that continued refinement and expansion of these programs can lead to further turnaround in utilization. - Dr. Ron Kurtz(CEO)

Contradiction Point 5

Pace and Nature of International Expansion

Contradiction on the expected contribution and timeline for international markets in 2026.

Jacqueline (Orrick), what are your thoughts on the company's recent financial performance? - Jacqueline (Orrick)

2026Q2: The company is open to offering more rental solutions... The strategy is to offer a range of solutions to customers. - Mark Wilterding(CFO)

How much of the LDD pipeline do you expect to shift toward rental units versus capital purchases in international markets? - Larry Biegelsen (Wells Fargo)

2026Q1: The international contribution in 2026 is not yet material enough to quantify specifically; the company will provide updates as traction builds. - Mark Wilterding(CFO)